RxDoctor Payments Data

Edward Morris, MD

Cardiovascular Disease · Washington, DCNPI 1437166394

Payments from drug & device makers

$473in general payments, 2019–2025

Across 14 payments — averaging $33.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$180
  • Novo Nordisk$120
  • Regeneron Healthcare Solutions, Inc.$60
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$55
  • Pfizer$25
  • Itamar Medical Inc$18
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$45496%
  • Education$194%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$473 in reported general payments places this provider in the 35th percentile of 105 cardiovascular disease providers in District of Columbia.

See all cardiovascular disease providers in District of Columbia

Medicare billing

Part B allowed, 2024
$542,659
Medicare patients
1,161
Services billed
4,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban222$262,391
EntrestoSacubitril/Valsartan132$166,233
JardianceEmpagliflozin78$113,268
Repatha SureclickEvolocumab68$75,352
XareltoRivaroxaban41$61,655
Ranolazine ErRanolazine46$8,025
Ezetimibe213$6,845
Rosuvastatin Calcium247$5,693
Metoprolol Succinate350$5,125
Nebivolol Hcl47$3,734
Clonidine13$3,277
Candesartan Cilexetil20$2,863
Verapamil SrVerapamil Hcl12$2,684
Diltiazem 24hr Er (La)Diltiazem Hcl13$2,143
Hydralazine Hcl125$1,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$262,391222 claims
Johnson & JohnsonXarelto$15$61,65541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 105 cardiovascular disease providers in District of Columbia.

Other cardiovascular disease in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →